SLC5A2 and hydrops fetalis: SGLT2 inhibitors were recommended as the first-line drugs for the treatment of HFrEF based on promising evidence from EMPEROR-Reduced and DAPA-HF studies (Colombo et al., 2020; Packer et al., 2020; Mcdonagh et al., 2021).